SandboxAQ
B2B/B2G enterprise SaaS + licensed software and government R&D contracts; LQM simulation (life sciences, materials, finance), AQtive Guard PQC management subscription, and AQNav quantum-navigation systems sold to defense/aerospace and CHIPS-funded materials discovery.
Company rarely discloses post-money officially; Feb-2023 (~$4B) is a PitchBook estimate and the Apr-2025 Series E (~$5.75B) is secondary-reported (Forge cites $5.78B), not company-confirmed. The 2026 ~$5.2B is a Forge/market-implied secondary mark, not a priced round.
Earnings, margins, COGS & capex
Revenue trend
Margins
Bull & bear
A rare enterprise-grade AI/quantum company with real federal anchor demand: the June-2026 $500M CHIPS materials-discovery award, multi-year DoW post-quantum cryptography work, and AQNav USAF GPS-denied-navigation contracts give it durable B2G revenue and validation most quantum pure-plays lack — while its 'Large Quantitative Models' position it in the commercial AI wave, not just speculative quantum hardware.
- $500M CHIPS R&D award (Jun-17-2026, Dept of Commerce/NIST) funds AI-driven semiconductor-materials discovery (PFAS replacements, catalysts, rare-earth-free magnets, batteries) — a non-dilutive, mission-anchored revenue stream with the U.S. government taking a minority equity stake, signaling strategic-asset status.
- Diversified product surface (LQMs, AQtive Guard PQC, AQNav navigation, CardiAQ magnetocardiography) means it is not betting on one quantum modality; software runs on rented Google Cloud / NVIDIA compute, so it avoids the capital sink of building QPUs.
- Blue-chip cap table and validation: Alphabet spinout chaired by Eric Schmidt, backed by Google, NVIDIA, Ray Dalio, T. Rowe Price, Marc Benioff, BNP Paribas, Yann LeCun — ~$950M raised, ~$5.75B last mark (Apr-2025).
- Post-quantum cryptography (AQtive Guard) rides a regulatory tailwind: NIST PQC standards finalized and federal/enterprise migration mandates create non-discretionary demand; deployed with SoftBank, Vodafone, and the Department of War (5-year agreement).
- Real defense pull on AQNav: USAF TACFI contract extension for GPS-jamming/spoofing-resistant magnetic-anomaly navigation, DIU Transition of Quantum Sensing program, NATO DIANA — a credible dual-use moat as GPS denial becomes a frontline problem.
Valuation is extreme versus disclosed traction: a ~$5.75B mark against an estimated ~$17.8M of ARR (~320x) means the price embeds a decade of flawless execution across four unproven frontier markets. The story spans PQC, quantum navigation, drug/materials discovery, and medical devices — breadth that reads as a science conglomerate searching for a scaled commercial business, with most revenue still grant/contract-shaped rather than recurring SaaS.
- ~320x trailing ARR on a ~$17.8M FY2024 secondary estimate — even at aggressive growth, the multiple demands the company become a multi-billion-revenue platform; the official revenue is undisclosed, so the true gap may be worse.
- Strategy breadth is a risk, not just an asset: PQC, navigation, materials, and cardiac imaging are four different go-to-markets, sales motions, and regulatory regimes; a 352-person company spread this thin risks being subscale in each.
- Government dependence cuts both ways: the $500M CHIPS award and defense contracts make revenue policy- and appropriation-sensitive (administration change, CHIPS reauthorization, procurement timelines) and lumpy versus durable commercial SaaS; the federal equity stake also adds governance complexity ahead of any IPO.
- Crowded, well-capitalized competition in every lane — Quantinuum (full PQC+hardware stack), PQShield (taped-out PQC silicon), Q-CTRL/Infleqtion/IonQ (quantum navigation & sensing), and Big Tech (IBM, Google, Microsoft) in PQC/quantum — limits pricing power and any single durable moat.
- No near-term IPO (estimates 2027–2030) and continued cash burn imply further dilution; pre-IPO secondary marks are thin and illiquid, and the 2025/2026 financials are not public, so the bull case rests on unverifiable internal numbers (P-2/P-5 honesty caveat).
What it is worth
Pre-IPO last-round mark + revenue-multiple sanity check (no public market price). Reverse-multiple read: ~$5.75B on ~$17.8M est. ARR ≈ ~320x trailing — only justifiable if ARR compounds to hundreds of millions within ~3–5 years across PQC + navigation + materials.
~$2.5–4B
quantum/AI hype de-rates private marks, a CHIPS/defense appropriation wobble or competitive loss in PQC/navigation forces a down-round before liquidity.
~$5.5–6B
flat-to-modestly-up from the Apr-2025 mark; execution proceeds but ARR stays sub-$100M and the multiple compresses toward growth-software norms.
~$8–10B
if CHIPS materials platform + PQC migration + AQNav scale ARR toward $150M+ and a 2027–2028 IPO catches a quantum/AI-for-science bid (still a steep forward multiple).
Headline = last priced round (Series E, ~$5.75B, Apr-2025), modestly above the Dec-2024 ~$5.6B round. The $500M CHIPS award and federal equity stake support a strategic-premium but do NOT re-rate ARR; financials are undisclosed so the multiple uses a secondary estimate. Bands frame a wide private-mark range, not a public target.
SWOT
Strengths
- Alphabet pedigree + elite cap table (Google, NVIDIA, Eric Schmidt chair, Ray Dalio, T. Rowe Price, Marc Benioff, Yann LeCun) — capital access and credibility
- Anchor federal demand: $500M CHIPS materials award (Jun-2026), 5-yr DoW PQC agreement, USAF AQNav contracts
- Asset-light software model — rents Google Cloud / NVIDIA compute rather than building QPUs or fabs
- Riding two real tailwinds at once — enterprise AI (LQMs) and the mandated NIST post-quantum cryptography migration
Weaknesses
- Tiny disclosed revenue (~$17.8M ARR FY2024 est.) versus a ~$5.75B mark — ~320x
- Strategy spread across 4+ unrelated frontier markets at only ~352 employees — subscale risk per lane
- Revenue is contract/grant-shaped and lumpy, not predominantly recurring SaaS
- 2025/2026 financials undisclosed — limited transparency for valuation
Opportunities
- NIST PQC standards drive a non-discretionary federal + enterprise cryptography-migration cycle
- GPS-denied navigation (AQNav) as a frontline defense need amid jamming/spoofing warfare
- LQMs for drug/materials discovery as a commercial AI-for-science category alongside the CHIPS award
- CardiAQ magnetocardiography — a large medtech TAM if it clears clinical/regulatory validation
Threats
- Well-funded competition in every segment (Quantinuum, PQShield, Q-CTRL, Infleqtion, IonQ, IBM, Google, Microsoft)
- Policy/appropriation risk on CHIPS and defense budgets; federal equity stake complicates governance
- Quantum/AI hype-cycle de-rating could compress private marks before a 2027–2030 IPO
- Dilution risk — continued burn and no near-term liquidity event
Moats, dependencies & bottlenecks
Moats
Dependencies
Top signals & trends
Top signals
Largest single validation/funding event post-cutoff; anchors materials-discovery revenue and signals strategic-asset status.
Up modestly from ~$5.6B (Dec-2024) — flat-to-slightly-up marks in a tough quantum funding tape; cap table deepened.
Secondary estimate (getlatka); official not disclosed. Multiple prices in near-flawless multi-market execution.
Real defense pull for magnetic-anomaly navigation as GPS jamming/spoofing escalates.
NIST PQC standards create mandated migration demand — a non-discretionary buyer base.
Long liquidity horizon; further dilution likely; valuation rests on unverifiable internal numbers.
Breadth risks subscale execution in each lane; reads as a science conglomerate pre-scale-commercialization.
Trends
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
GPU compute for LQM training/inference; also a Series E investor — supplier + backer.
Parent-of-origin (2022 spinout); LQMs offered on Google Cloud (Jan-2025) — cloud-compute supplier + investor.
Hyperscale cloud capacity is the key input for physics-simulation compute (analysis — primary cited supplier is Google Cloud).
Used AQtive Guard to find cryptographic/certificate vulnerabilities across large-scale networks (non-US; analysis).
Early PQC/cryptography-management customer (non-US; analysis).
AQNav GPS-denied navigation contracts + 5-yr PQC agreement — anchor B2G customer.
$500M materials-discovery award (Jun-2026); also takes a minority equity stake.
Launch healthcare customer; CardiAQ clinical collaborations at Mayo Clinic, UCSF.
Honeywell+Cambridge Quantum; closest PQC competitor with an integrated hardware+software quantum-safe stack. Private; reported preparing for IPO.
PQC pure-play; among the few to tape out a working post-quantum (ML-KEM/ML-DSA) test chip — hardware credibility SandboxAQ lacks. Private.
Trapped-ion quantum public co.; acquired Vector Atomic (Oct-2025) to push into quantum sensing/navigation — direct AQNav overlap.
Leads quantum navigation with Ironstone Opal — direct AQNav competitor in GPS-denied navigation. Private.
Atomic clocks (Tiqker) and quantum sensing; competes in the navigation/timing-sensing lane. Private; SPAC-merger path discussed.
Co-developed NIST lattice PQC standards; offers quantum-safe transformation services — a deep-pocketed PQC competitor for enterprise/federal.
Michele Mosca's quantum-safe advisory/risk firm — competes in PQC migration consulting and risk assessment. Private.
Not a quantum company but competes for the same AI-for-government/defense budget and enterprise materials/simulation mind-share.